Greenwich LifeSciences is a clinical-stage biopharmaceutical company developing an immunotherapy to prevent breast cancer recurrences. The company’s value rests on its single product candidate, GLSI-100, which targets HER2/neu positive patients. GLSI-100 combines a GP2 peptide fragment with an immunoadjuvant to stimulate T cells to destroy cancer cells. Patients receive the therapy through a series of 11 injections over roughly 2.5 years, beginning after completing the first year of standard trastuzumab-based treatment. Greenwich focuses on a specific patient sub-population that is HLA-A*02 positive and has high-risk disease, representing roughly 6.25% of breast cancer surgery patients. The company is currently conducting Flamingo-01, a global Phase III trial across the U.S. and Europe. Prior Phase IIb data indicated a substantial reduction in recurrence rates with no serious adverse events attributed to the drug. Greenwich is a pre-revenue company that funds operations through external financing, with nearly all spending dedicated to the Flamingo-01 trial. The company holds an exclusive worldwide license for the GP2 technology and owes milestones and royalties upon commercialization. Greenwich plans to use third-party contract manufacturers for production and is considering building an internal sales force or partnering with larger firms for global distribution.